Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Panbela Therapeutics, Inc.
< Previous
1
2
Next >
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
July 30, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
June 24, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
June 10, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
May 06, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
May 01, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
April 30, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
April 22, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Poster Presentation at American Association for Cancer Research:
April 18, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Transfer to OTCQB Market
April 16, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
March 12, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
February 15, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Closing of Approximately $9.0 Million Public Offering
February 01, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
January 30, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
January 29, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
January 25, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
January 18, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
January 16, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market
December 21, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
December 18, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
December 04, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
November 29, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
November 03, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
November 02, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
October 31, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
October 25, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023
October 24, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
September 26, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela to Present at the LD Micro Investor Conference
September 19, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
September 05, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.